Growth Metrics

Crescent Biopharma (CBIO) FCF Margin (2013 - 2026)

Crescent Biopharma (CBIO) reported FCF Margin of 870.74% for Q1 2026, up 95.99% on a QoQ basis from 21695.8% in Q2 2022.

Crescent Biopharma (CBIO) has 8 years of FCF Margin data on file, last reported at 870.74% in Q1 2026.

  • Quarterly FCF Margin changed N/A year-over-year to 870.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6709.05% (changed N/A YoY) and the FY2025 annual result came in at 659.45%, changed N/A from the prior year.
  • FCF Margin advanced to 870.74% in Q1 2026 per CBIO's latest filing, from 21695.8% in the prior quarter.
  • Across five years, FCF Margin topped out at 870.74% in Q1 2026 and bottomed at 21695.8% in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -3.98%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 43.35%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 23.53%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 4.17%
10 Crescent Biopharma 569.36 Mn 380.20 Mn - -870.74%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -870.74%
Jun 30, 2022 -21,695.80%
Dec 31, 2021 -72,675.25%
Sep 30, 2021 -19,582.49%
Jun 30, 2021 -9,589,105.63%
Mar 31, 2021 -1,338.62%
Dec 31, 2020 -5,980.21%
Sep 30, 2020 -1,150.00%
Mar 31, 2020 -38.98%
Sep 30, 2016 -40,330.17%
Dec 31, 2015 -19,676.90%
Sep 30, 2015 38,178.15%
Jun 30, 2015 -31.74%
Jun 30, 2014 60.77%
Dec 31, 2013 -7,205.59%
Sep 30, 2013 -6,521.65%
Jun 30, 2013 -4,959.27%
Mar 31, 2013 -101.99%